InflaRx (IFRX) Other Working Capital Changes (2017 - 2026)
InflaRx (IFRX) posted Other Working Capital Changes of -$87443.0 for Q1 2026, down 3.29% sequentially from -$84656.2 in Q4 2025, and up 16.95% YoY from -$74769.1 in Q1 2025.
InflaRx (IFRX) Other Working Capital Changes (2017 - 2026) Analysis & Trends
InflaRx has reported Other Working Capital Changes for 11 years, with the latest figure at -$87443.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 16.95% year-over-year to -$87443.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$384391.5 (up 11.06% YoY) and the FY2025 annual result came in at -$404001.3, up 3.83% from the prior year.
- Other Working Capital Changes declined to -$87443.0 in Q1 2026 per IFRX's latest filing, from -$84656.2 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $8.1 million in Q1 2023 and troughed at -$6.5 million in Q4 2022.
- A 5-year average of $497996.2 and a median of -$75224.0 in 2025 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes slipped 16.6% in 2024, then increased 19.14% in 2025.
- Over 5 years, Other Working Capital Changes stood at -$93187.4 in 2022, then fell by 9.57% to -$102108.8 in 2023, then fell by 2.53% to -$104689.2 in 2024, then increased by 19.14% to -$84656.2 in 2025, then retreated by 3.29% to -$87443.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$87443.0, -$84656.2, and -$99314.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -190,408.90 |
| Mar 31, 2026 | -190,408.90 |
| Mar 31, 2026 | -190,408.90 |
| Dec 31, 2025 | 3.11 Mn |
| Dec 31, 2025 | 3.11 Mn |
| Dec 31, 2025 | 3.11 Mn |
| Sep 30, 2025 | -75,224.02 |
| Sep 30, 2025 | -75,224.02 |
| Sep 30, 2025 | -75,224.02 |
| Jun 30, 2025 | -21,678.16 |
| Jun 30, 2025 | -21,678.16 |
| Jun 30, 2025 | -21,678.16 |
| Mar 31, 2025 | -409,380.80 |
| Mar 31, 2025 | -409,380.80 |
| Mar 31, 2025 | -409,380.80 |
| Dec 31, 2024 | -867,205.77 |
| Dec 31, 2024 | -867,205.77 |
| Dec 31, 2024 | -867,205.77 |
| Sep 30, 2024 | 729,439.59 |
| Sep 30, 2024 | 729,439.59 |